Narisara Tribuddharat
Research Subjects
Narisara Tribuddharat has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ben Thiravetyan
Department of Internal Medicine Texas Tech University Health Sciences Center Lubbock Texas USA
1 shared publication - Leenhapong Navaravong
Intermountain Health Utah Valley Hospital, Provo, USA
1 shared publication - Surachat Jaroonpipatkul
Division of Cardiology, Rajavithi Hospital, College of medicine Rangsit University, Bangkok, Thailand
1 shared publication - Tanawat Attachaipanich
Cardiac Electrophysiology Research and Training Center, Chiang Mai University, Chiang Mai 50200, Thailand
1 shared publication
Latest Publications
- Open Access
- 30 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2635
Premature Ventricular Contraction-Induced Cardiomyopathy: Contemporary Evidence from Risk Stratification, Pathophysiology, and Management
Premature ventricular complexes (PVCs) are commonly encountered problems in clinical settings. The range of symptoms can be from asymptomatic to palpitations, fatigue, or heart failure symptoms. A higher burden of PVCs is a risk factor for development of PVC-induced cardiomyopathy (PIC). Rhythm evaluation by 12-lead ECG and an ambulatory monitoring device are essential. Currently, several imaging modalities, such as echocardiography and cardiac magnetic resonance imaging, are utilized to evaluate the underlying structure that may be related to PIC. Beta blockers and antiarrhythmic drugs are typically part of the initial management strategy. If these fail, catheter ablation of PVCs is typically the next step. The purpose of this article is to summarize the current evidence/knowledge about PIC.
- 30 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2635
Open AccessPremature Ventricular Contraction-Induced Cardiomyopathy: Contemporary Evidence from Risk Stratification, Pathophysiology, and Management
Premature ventricular complexes (PVCs) are commonly encountered problems in clinical settings. The range of symptoms can be from asymptomatic to palpitations, fatigue, or heart failure symptoms. A higher burden of PVCs is a risk factor for development of PVC-induced cardiomyopathy (PIC). Rhythm evaluation by 12-lead ECG and an ambulatory monitoring device are essential. Currently, several imaging modalities, such as echocardiography and cardiac magnetic resonance imaging, are utilized to evaluate the underlying structure that may be related to PIC. Beta blockers and antiarrhythmic drugs are typically part of the initial management strategy. If these fail, catheter ablation of PVCs is typically the next step. The purpose of this article is to summarize the current evidence/knowledge about PIC.